Skip to main navigation
AnaptysBio
Investor Relations
About
Overview
Strategy
Management
Board of Directors
Research and Development Committee
Contact
Technology
Therapeutic Antibodies
Somatic Hypermutation
SHM Platform
Key Advantages
Publications
Pipeline
Overview
Imsidolimab
Rosnilimab
ANB032
Partnerships
Investors / News
Overview
News
Events
Presentations
Governance
Stock Information
Analyst Coverage
SEC Filings
Investor FAQs
Contact
Careers
Overview
Job Openings
Health and Financial Benefits Overview
Contact
Toggle
Presentations
Presentations
AnaptysBio Corporate Presentation January 2023
Tools
Print
Print
Email
Email
RSS Feeds
RSS Feeds
Email Alerts
Email Alerts
Investor Contact
Investor Contact
Document Request
Document Request